Jakafi 15mg

Jakafi 15 mg (Ruxolitinib) is an antitumor remedy, is an inhibitor of protein kinase. Jakafi 15 mg is used in the treatment of myelofibrosis, including primary and secondary, which developed due to true polycythemia and essential thrombocythemia. According to the research, the using of Jakafi 15 mg helps to reduce the size of the spleen in patients by 35% (compared with 0.7% in the placebo group), increases the duration and quality of life, and reduces symptoms. If you compare Jakafi 15 mg with the best available therapy, the toxicity of the remedy is moderate. The research data show that, most often, among the patients taking Jakafi 15 mg, the most serious and common side effects were anemia (in 5% of cases) and pneumonia.

Dosing and Administration

Inside. Regardless of food intake.
The recommended initial dose of the remedy may be 15 mg and 20 mg. The frequency of taking the remedy is two times a day. The maximum dose of Jakafi 15 mg is 25 mg / day.
Selection of the dose of the remedy is carried out based on the safety and effectiveness of the therapy.
It is recommended to reduce the dose in case of a decrease in the number of platelets less than 100×109 / l, in order to prevent the suspension of therapy due to the development of thrombocytopenia.
The using of Jakafi 15 mg is relevant only if the positive therapeutic effect remains.
During treatment (and also before the appointment of Jakafi 15 mg), it is necessary to count the blood cells.
In renal failure, the initial dose, which should be based on the number of platelets, should be reduced by approximately 50%. Patients with severe renal failure should be closely monitored.

In liver failure, the initial dose, which should be based on the number of platelets, should be reduced by approximately 50%. Patients with severe hepatic impairment should be closely monitored.

Special instructions

Before the appointment of Jakafi 15 mg, a general blood test should be performed. The using of Jakafi 15 mg can provoke such hematologic adverse reactions as thrombocytopenia, anemia and neutropenia.
In case of anemia, transfusion of erythrocyte mass may be necessary. In this case, the dose of the remedy can be adjusted. In the course of the study, approximately 50% of patients who received Jakafi 15 mg needed a red blood cell transfusion (compared with 37% in the control group).
Neutropenia, on the whole, is reversible. This undesirable effect can be quenched by temporarily discontinuing the remedy.